Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 217
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Hideki Fujii, Norifumi Kawada
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3863-3863
Open Access | Times Cited: 212
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Stergios A. Pοlyzos, Eun Seok Kang, Chrysoula Boutari, et al.
Metabolism (2020) Vol. 111, pp. 154203-154203
Closed Access | Times Cited: 124
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
Anastasia‐Stefania Alexopoulos, Matthew J. Crowley, Ying Wang, et al.
Hepatology (2021) Vol. 74, Iss. 3, pp. 1220-1233
Open Access | Times Cited: 89
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 84
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107723-107723
Open Access | Times Cited: 77
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
John A. Dougherty, Erenie Guirguis, Krisy‐Ann Thornby
Annals of Pharmacotherapy (2020) Vol. 55, Iss. 1, pp. 65-79
Closed Access | Times Cited: 70
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 43
The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
Rossella Palma, Annamaria Pronio, Mario Romeo, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3649-3649
Open Access | Times Cited: 41
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 10
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung‐Wan Lee, Yong‐ho Lee, Cheol‐Young Park, et al.
Diabetes & Metabolism Journal (2020) Vol. 44, Iss. 3, pp. 382-382
Open Access | Times Cited: 58
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, et al.
Hepatology (2021) Vol. 75, Iss. 6, pp. 1523-1538
Closed Access | Times Cited: 47
Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition
Chen Jian, Xiaoqin Ding, Ruoyun Wu, et al.
Journal of Agricultural and Food Chemistry (2021) Vol. 69, Iss. 47, pp. 14176-14191
Closed Access | Times Cited: 46
Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016
Haojie Zhang, Yuying Wang, Chi Chen, et al.
Chinese Medical Journal (2021) Vol. 134, Iss. 13, pp. 1593-1601
Open Access | Times Cited: 45
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 45
Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
Cheng Han Ng, Snow Yunni Lin, Yip Han Chin, et al.
Endocrine Practice (2021) Vol. 28, Iss. 2, pp. 223-230
Closed Access | Times Cited: 40
GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Shahla Rezaei, Reza Tabrizi, Peyman Nowrouzi‐Sohrabi, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 40
Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
Sara Jarmakiewicz-Czaja, Aneta Sokal, Piotr Pardak, et al.
Canadian Journal of Gastroenterology and Hepatology (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 29
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
Habib Yaribeygi, Mina Maleki, Željko Reiner, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6544-6544
Open Access | Times Cited: 28
Impact of fenofibrate on NAFLD/NASH: A genetic perspective
Ali Mahmoudi, Tannaz Jamialahmadi, Thomas P. Johnston, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 8, pp. 2363-2372
Closed Access | Times Cited: 27
A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
Dana Ivancovsky‐Wajcman, Christopher J. Byrne, John Dillon, et al.
Hepatology (2024)
Open Access | Times Cited: 5
Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine
Yanqi Dang, Jingjuan Xu, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 127, pp. 109976-109976
Open Access | Times Cited: 46
Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis
Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 26
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101182-101182
Open Access | Times Cited: 13
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won‐Young Lee
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 327-339
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top